Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625212 | 0.90 | NPC1 (0.60) | RAB9ANPC1DGAT1ATR | |
| SCHEMBL1624266 | 0.81 | NPC1 (0.60) | RAB9ANPC1ATR | |
| SCHEMBL2169030 | 0.81 | MAPT (0.78) | KCNQ3KCNQ2RAB9ANPC1DGAT1 | |
| SCHEMBL1625531 | 0.81 | TRPV1 (0.51) | KCNQ3KCNQ2RAB9ANPC1 | |
| SCHEMBL1624353 | 0.81 | TRPV1 (0.51) | KCNQ3KCNQ2RAB9ANPC1 | |
| SCHEMBL6926900 | 0.80 | CNR2 (0.53) | MAPTHTTATR | |
| SCHEMBL1624888 | 0.80 | NPC1 (0.50) | RAB9ANPC1DGAT1ATR | |
| SCHEMBL1625106 | 0.79 | HDAC1 (0.46) | RAB9ANPC1DGAT1MAPTSMN1; SMN2 | |
| SCHEMBL13229247 | 0.76 | DGAT1 (0.63) | KCNQ3KCNQ2RAB9ANPC1DGAT1 | |
| SCHEMBL774365 | 0.75 | MAPT (0.65) | KCNQ3KCNQ2RAB9ANPC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | claimed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | claimed |
| EP-2044065-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | claimed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | claimed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-7928133-B2 | Compounds and compositions as hedgehog signaling pathway modulators | IRM LLC (BM) | 2011-04-19 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| CN-101501004-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (VG) | 2009-08-05 | — | — | CN | disclosed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | GLI1, SHH, SMO | KCNQ3 3757/4885KCNQ2 3561/4885RAB9A 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.